Nasdaq:ALBT
Avalon GloboCare Corp.
A small-cap medical device manufacturer specializing in surgical navigation and robotic solutions for orthopedic and spine procedures.
Key Metrics
Investment Thesis
Bull Case
Investors might consider ALBT if they believe the company can successfully scale its niche surgical navigation technology into higher volume markets, potentially utilizing the existing $2.9M cash balance to fund a turnaround before requiring additional dilutive financing.
Bear Case
The stock is highly speculative given the substantial accumulated deficit of nearly $88M, negative operating cash flows, and current liabilities that dwarf liquid assets, suggesting a high probability of further capital raising or financial distress without immediate profitability.
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (ALBT) is a US-based medical technology company focused on developing and manufacturing advanced medical devices, primarily in the areas of surgical navigation and robotic surgery systems.
Analysis
Management Discussion
Despite a notable improvement in net loss narrowing from $16.7M in 2023 to $7.9M in 2024, the company continues to burn cash with negative operating cash flows of $5.0M and minimal revenue growth over the past three years, indicating that profitability remains elusive.
Industry Overview
The medical device industry is characterized by high regulatory barriers, intense competition from established giants, and a reliance on third-party payer reimbursement policies that can significantly impact revenue stability for smaller innovators.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $1.2M | $1.3M | $1.3M |
| Cost of Revenue | $929.4K | $0 | $0 |
| Gross Profit | $272.7K | $1.3M | $1.3M |
| Operating Expenses | $9.1M | $17.0M | $6.3M |
| Operating Income | $-8.8M | $-15.8M | $-4.9M |
| R&D | $731.3K | $109.6K | — |
| Stock-Based Comp | $1.1M | $1.2M | $521.5K |
| Depreciation | $330.7K | $211.7K | $177.9K |
| Amortization | — | — | $666.9K |
| Other OpEx | $8.3M | $16.9M | — |
| Non-Operating Income | $-3.1M | $-953.3K | $-3.0M |
| Interest Expense | $176.0K | — | — |
| Pre-Tax Income | $-11.9M | $-16.7M | $-7.9M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-11.9M | $-16.7M | $-7.9M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-11.9M | $-16.7M | $-7.9M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-11.9M | $-16.7M | $-7.9M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $2.4M | $850.9K | $3.2M |
| Cash & Equivalents | $2.0M | $285.4K | $2.9M |
| Prepaid Expenses | — | $368.0K | $299.4K |
| Other Current Assets | $382.6K | $197.5K | $80.8K |
| Long-Term Assets | $17.4M | $19.7M | $17.7M |
| PP&E (Net) | $138.3K | $38.1K | $12.9K |
| Intangibles | — | $9.4M | $8.7M |
| Operating Leases | $10.9K | $128.2K | $4.7K |
| Other LT Assets | $16.7M | $-1.9M | $-1.6M |
| Total Assets | $19.8M | $20.6M | $21.0M |
| Current Liabilities | $3.6M | $6.8M | $13.9M |
| Current Leases | $11.4K | $129.4K | $10.7K |
| Other Current Liab | $3.6M | $6.6M | $13.9M |
| Long-Term Liabilities | $5.0M | $6.5M | $0 |
| LT Operating Leases | — | $4.9K | — |
| Other LT Liab | $2.6M | $6.4M | — |
| Total Liabilities | $8.6M | $13.2M | $13.9M |
| Shareholders' Equity | $11.2M | $7.4M | $7.1M |
| Paid-In Capital | — | $67.9M | $72.0M |
| Retained Earnings | $-63.1M | $-79.8M | $-87.7M |
| AOCI | $-213.1K | $-231.7K | $-232.0K |
| Treasury Stock | $522.5K | $522.5K | — |
| Total L&E | $19.8M | $20.6M | $21.0M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-11.9M | $-16.7M | $-7.9M |
| Non-Cash Adjustments | $3.8M | $9.7M | $4.3M |
| Working Capital Changes | $1.1M | $522.7K | $-1.3M |
| Cash from Operations | $-7.0M | $-6.5M | $-5.0M |
| Capital Expenditures | $1.7K | $22.2K | — |
| Cash from Investing | $-9.1M | $-22.2K | $-100.0K |
| Cash from Financing | $17.3M | $4.8M | $7.6M |
| FX Effect | $10.1K | $-4.0K | $1.4K |
| Net Change in Cash | $1.2M | $-1.7M | $2.6M |
| Beginning Cash | $807.5K | $2.0M | $285.4K |
| Ending Cash | $2.0M | $285.4K | $2.9M |
Frequently Asked Questions
How does Avalon GloboCare Corp. make money?
The company generates revenue through the sale of proprietary surgical navigation platforms and robotic systems used by hospitals for complex orthopedic and spinal surgeries, with recent annual revenues stabilizing around $1.3M while managing significant operating expenses.
What are the main risks for ALBT?
The company faces severe liquidity constraints with current liabilities significantly exceeding current assets, suffers from consistent net losses eroding the substantial retained earnings deficit, operates with minimal cash reserves despite high capital needs for R&D, and is exposed to regulatory reimbursement risks in the US healthcare sector.
What is ALBT's competitive advantage?
ALBT leverages proprietary intellectual property in surgical navigation technology that offers precision benefits over generic alternatives, maintains a lean cost structure relative to large competitors, and targets niche markets underserved by major medical device conglomerates.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.